Please provide your email address to receive an email when new articles are posted on . Lenalidomide maintenance therapy significantly improved PFS compared with observation among patients with newly ...

Lenalidomide (Revlimid)-induced second primary malignancies appear to be limited to patients with multiple myeloma, according to a systematic review and meta-analysis. While there was no significant ...

Data from a large phase III trial presented at the 2022 American Society of Hematology (ASH) annual meeting examined the relationship between minimal residual disease, progression-free survival, and ...

A prospective subgroup analysis of two prospective, randomized, double-blind, placebo-controlled phase III clinical trials showed that the combination of lenalidomide plus dexamethasone is superior to ...

New treatments for multiple myeloma have greatly increased survival, and this longer life expectancy has led to renewed concern about the risk for secondary malignancies. There was no difference in ...

Please provide your email address to receive an email when new articles are posted on . The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly ...

Epcoritamab plus rituximab/lenalidomide significantly improved PFS and ORR compared with rituximab/lenalidomide alone. The Food and Drug Administration (FDA) has approved Epkinly ® (epcoritamab-bysp), ...

Combination tafasitamab, lenalidomide, and rituximab is a recommended second-line regimen based on the phase 3 InMIND trial. The clinical data supporting the addition of tafasitamab to lenalidomide ...